ArriVent BioPharma, Inc. (AVBP) Dividend History

Company News

• ArriVent Posts Wider Loss in Fiscal Q2

  ArriVent BioPharma reported a wider net loss in Q2 2025, with increased R&D expenses driven by clinical pipeline expansion and a strategic partnership. The company continues developing firmonertinib for non-small cell lung cancer and initiated a new antibody-drug conjugate program.

  The Motley Fool
• ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

  ArriVent BioPharma announced a public offering of 2,482,692 common stock shares and pre-funded warrants, expecting to raise approximately $75 million to support its drug development programs, particularly firmonertinib.

  GlobeNewswire Inc.

  Featured Companies: C
• $10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying

  Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Vera Therapeutics The Trade: Vera Therapeutics, Inc. (NASDAQ: VERA) Director Maha Katabi acquired a total of 161,290 shares an average price of $31.00. To acquire these shares, it cost around $5 million. What’s Happening: Vera Therapeutics priced its upsized public offering of ...

  Benzinga

  Featured Companies: CLF KALV VERA